en Dinapsoline

Dinapsoline
Clinical data
ATC code	none;
Identifiers
	IUPAC name 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline;
CAS Number	458563-40-1 ;
PubChem CID	9816455;
ChemSpider	7992205 ;
UNII	GZ9XC6C5P9;
CompTox Dashboard (EPA)	DTXSID50431229 ;
Chemical and physical data
Formula	C16H15NO2
Molar mass	253.301 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1c3c(ccc1O)[C@H]4c2c(cccc2C3)CNC4;
	InChI InChI=1S/C16H15NO2/c18-14-5-4-11-12(16(14)19)6-9-2-1-3-10-7-17-8-13(11)15(9)10/h1-5,13,17-19H,6-8H2/t13-/m0/s1 ; Key:ZQTSNGJHMUKLOM-ZDUSSCGKSA-N ;
	(what is this?) (verify)

Dinapsoline is a drug developed for the treatment of Parkinson's disease,^[1] that acts as a selective full agonist at the dopamine D₁ receptor.^[2]^[3]^[4]^[5]

References

^ Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338–44. PMID 11160615.
^ Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (January 1996). "9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore". Journal of Medicinal Chemistry. 39 (2): 549–55. doi:10.1021/jm950707+. PMID 8558526.
^ Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (August 2002). "(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist". Journal of Medicinal Chemistry. 45 (17): 3660–8. doi:10.1021/jm0101545. PMID 12166939.
^ Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (February 2004). "Synthesis and SAR exploration of dinapsoline analogues". Bioorg. Med. Chem. 12 (4): 715–34. doi:10.1016/j.bmc.2003.11.015. PMID 14759732.
^ Gleason SD, Witkin JM (May 2006). "Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine". Psychopharmacology. 186 (1): 25–31. doi:10.1007/s00213-006-0342-2. PMID 16575553. S2CID 2159983.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid11160615-1] Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 296 (2): 338–44. PMID 11160615.

[pmid8558526-2] Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE (January 1996). "9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore". Journal of Medicinal Chemistry. 39 (2): 549–55. doi:10.1021/jm950707+. PMID 8558526.

[pmid12166939-3] Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G (August 2002). "(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist". Journal of Medicinal Chemistry. 45 (17): 3660–8. doi:10.1021/jm0101545. PMID 12166939.

[pmid14759732-4] Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB (February 2004). "Synthesis and SAR exploration of dinapsoline analogues". Bioorg. Med. Chem. 12 (4): 715–34. doi:10.1016/j.bmc.2003.11.015. PMID 14759732.

[pmid16575553-5] Gleason SD, Witkin JM (May 2006). "Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine". Psychopharmacology. 186 (1): 25–31. doi:10.1007/s00213-006-0342-2. PMID 16575553. S2CID 2159983.

[1]

[2]

[3]

[4]

[5]